Dohn, Line H <br/><br/>
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.  [electronic resource] 

 -  Acta oncologica (Stockholm, Sweden)  Apr 2010 
 - 395-6 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1651-226X 
<br/><br/><label>Standard No.: </label>10.3109/02841860903428184  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab<br/>Camptothecin--administration & dosage<br/>Capecitabine<br/>Colorectal Neoplasms--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Drug Administration Schedule<br/>Feasibility Studies<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Infusions, Intravenous<br/>Leucovorin--administration & dosage<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Retrospective Studies<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome